Sorbitol
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
- Sorbitol
- Pharmacist Assessment Report
- Sorbitol: From an Unspecified Original Indication to Exercise-Induced Malignant Hyperthermia
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Sorbitol: From an Unspecified Original Indication to Exercise-Induced Malignant Hyperthermia
One-Sentence Summary
Sorbitol is a sugar alcohol that is marketed in Canada in irrigation products, and no formal original indication is recorded in the data compiled for this report. The TxGNN model predicts it may be effective for exercise-induced malignant hyperthermia. This prediction has 0 clinical trials and 0 publications behind it, so it rests on the computational score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (the Canadian licence records contain no approved indication text) |
| Predicted New Indication | Exercise-induced malignant hyperthermia |
| TxGNN Prediction Score | 0.9940 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 2 of 2) |
| Number of DINs | 2 (marketed: 2) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Sorbitol is known as a sugar alcohol used as an osmotic laxative, a sweetener and an irrigating solution. No original therapeutic indication is documented in the data compiled for this report.
Malignant hyperthermia is a disorder of calcium regulation in skeletal muscle, typically linked to RYR1 or CACNA1S variants. It is triggered by volatile anaesthetics or succinylcholine, and the established treatment is dantrolene. No plausible pharmacological link between sorbitol and this pathway has been identified.
The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. It should not be read as true pharmacological activity. Sorbitol is not a recognized treatment or preventive agent for malignant hyperthermia.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 00498807 | Sorbitol Mannitol Irrigation | Not specified | Not specified |
| 00799963 | Cystosol W 3% Hexitols | Not specified | Not specified |
Safety Considerations
- Contraindications (knowledge-graph based, not label text): The TxGNN knowledge graph lists active peptic ulcer disease as a contraindication.
- Drug Interactions: Two interactions were identified.
- Tolevamer: Major
- Lamivudine: Moderate
Package insert warnings and contraindications were not available for this report. Please refer to the Health Canada package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The only support for this prediction is a high model score. There are no clinical trials or publications, no documented mechanism, and no plausible pharmacological link between sorbitol and malignant hyperthermia. Dantrolene is the established treatment, and sorbitol has no recognised role.
To proceed, the following is needed:
- Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data from DrugBank
- Any preclinical or clinical evidence linking sorbitol to calcium regulation or thermoregulation in skeletal muscle
- Route and formulation compatibility assessment, since current Canadian products are irrigation solutions
- Review of whether the prediction is a TxGNN model (deep learning) artefact before any further investment
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.